IMUNON's Phase 3 ovarian cancer trial cleared to continue by safety panel

June 23, 2026 8:00 AM

IMUNON, Inc. (Nasdaq: IMNN) announced that an independent Data Monitoring Committee has recommended continuation of its Phase 3 OVATION 3 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found